---
schema_version: "secwatch.filing_event.v1"
accession: "0001367644-23-000199"
form_type: "8-K"
ticker: "EBS"
cik: "0001367644"
company_name: "Emergent BioSolutions Inc."
filed_at: "2023-11-28T23:59:59+00:00"
generated_at: "2026-06-07T20:55:45.421294+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Emergent BioSolutions gets $75M BARDA contract option for CYFENDUS anthrax vaccine

## Summary
- BARDA exercised a $75 million option under contract HHSO100201600030C for CYFENDUS (Anthrax Vaccine Adsorbed, Adjuvanted).
- Deliveries begin in 2023 and are expected to be complete by end of Q1 2024.
- CYFENDUS was approved by FDA in July 2023 as a two-dose post-exposure prophylaxis for ages 18+.
- The vaccine supports U.S. anthrax preparedness strategy and is part of Emergent's medical countermeasures franchise.

## SEC filing metadata
- accession: 0001367644-23-000199
- form_type: 8-K
- ticker: EBS
- cik: 0001367644
- company_name: Emergent BioSolutions Inc.
- filed_at: 2023-11-28T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1367644/000136764423000199/0001367644-23-000199-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1367644/000136764423000199/ebs-20231121.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001367644-23-000199
- JSON: https://secwatch.observer/filing/0001367644-23-000199.json
- Plain text: https://secwatch.observer/filing/0001367644-23-000199.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.